Vein360 Reprocessed LithoVue Digital Flexible Ureteroscope (Standard Deflection); Vein360 Reprocessed LithoVue Digital Flexible Ureteroscope (Reverse Deflection)
Vein 360 · Decision date Oct 20, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 20 October 2026 for K260708, a traditional 510(k) from Vein 360 of Cincinnati, Ohio, received 4 March 2026. The submission covers two named configurations: the Vein360 Reprocessed LithoVue Digital Flexible Ureteroscope (Standard Deflection) and the same device with Reverse Deflection. Both fall under regulation 876.1500, product code FGB, in the Gastroenterology/Urology specialty. SESE means clearance to market, not PMA approval.
The record identifies the products as reprocessed flexible ureteroscopes and does not describe the specific components, materials or changes assessed, nor any predicate comparison. The review was not handled by a third party, was not a combination product, and no predetermined change control plan was authorized. The linked summary document was not available in the public information, so performance data, indications and reprocessing validation remain unknown here.
The decision date is recorded as 2026-10-20, with the public page last updated 9 November 2026. No clinical or legal conclusions are drawn from the clearance.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Oct 20, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260708
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Vein 360
- Product code
- FGB
- Decision code
- SESE
- Decision date
- Oct 20, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Ureteroscope And Accessories, Flexible/Rigid.
FDA decision timeline
K260708 received
Application receipt date recorded by FDA.
K260708 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code FGB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Zhejiang Geyi Medical Instrument Co., Ltd. | 510(k) clearance | Oct 29, 2026 | FDA | |
CVAC Aspiration SystemK261447 | Calyxo, Inc. | 510(k) clearance | Sep 15, 2026 | FDA |
| Guangzhou Red Pine Medical Instrument Co., Ltd. | 510(k) clearance | Sep 9, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Vein 360
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Cincinnati, OH
Sources and methodology
- Original FDA record: K260708
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
